PL3845521T3 - Sposoby syntezy upadacytynibu i jego produktów pośrednich - Google Patents
Sposoby syntezy upadacytynibu i jego produktów pośrednichInfo
- Publication number
- PL3845521T3 PL3845521T3 PL19855338.0T PL19855338T PL3845521T3 PL 3845521 T3 PL3845521 T3 PL 3845521T3 PL 19855338 T PL19855338 T PL 19855338T PL 3845521 T3 PL3845521 T3 PL 3845521T3
- Authority
- PL
- Poland
- Prior art keywords
- upadacitinib
- synthesis methods
- synthesis
- methods
- Prior art date
Links
- WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 title 1
- 238000001308 synthesis method Methods 0.000 title 1
- 229950000088 upadacitinib Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811008444.4A CN110872250B (zh) | 2018-08-31 | 2018-08-31 | 两种化合物及其制备方法和在合成乌西替尼中的用途 |
| CN201811083531.6A CN110903254B (zh) | 2018-09-17 | 2018-09-17 | 一种应用于jak抑制剂类药物杂环中间体的合成方法 |
| PCT/CN2019/102443 WO2020043033A2 (zh) | 2018-08-31 | 2019-08-26 | 一种乌帕替尼及其中间体的合成方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3845521T3 true PL3845521T3 (pl) | 2025-03-10 |
Family
ID=69643168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19855338.0T PL3845521T3 (pl) | 2018-08-31 | 2019-08-26 | Sposoby syntezy upadacytynibu i jego produktów pośrednich |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11926633B2 (pl) |
| EP (1) | EP3845521B1 (pl) |
| ES (1) | ES2997858T3 (pl) |
| HR (1) | HRP20250035T1 (pl) |
| HU (1) | HUE069611T2 (pl) |
| PL (1) | PL3845521T3 (pl) |
| WO (1) | WO2020043033A2 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020202183A1 (en) | 2019-03-29 | 2020-10-08 | Mylan Laboratories Limited | The process for the preparation of upadacitinib and its intermediates |
| JP7648027B2 (ja) * | 2019-12-19 | 2025-03-18 | クリア、スペイン、エセ、ア、ウ | ウパダシチニブの調製のための方法及び中間体 |
| CN114621127A (zh) * | 2020-12-08 | 2022-06-14 | 苏州鹏旭医药科技有限公司 | 一种取代二氢吡咯的合成方法 |
| CN115417802A (zh) * | 2021-05-16 | 2022-12-02 | 上海鼎雅药物化学科技有限公司 | 乌帕替尼及其中间体的制备方法 |
| CN117285537B (zh) * | 2023-11-27 | 2024-02-06 | 中节能万润股份有限公司 | 一种乌帕替尼的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007006103A (es) | 2004-11-22 | 2007-07-20 | Vertex Pharma | Pirrolopirazinas y pirazolopirazinas de utilidad como inhibidores de proteinquinasas. |
| CN102711476B (zh) * | 2009-12-01 | 2014-12-03 | Abbvie公司 | 新的三环化合物 |
| WO2013043826A1 (en) | 2011-09-21 | 2013-03-28 | Abbvie Inc. | Tricyclic compounds useful as protein kinase inhibitors |
| CN106432246B (zh) | 2015-08-05 | 2020-07-07 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| CN116270646A (zh) | 2015-10-16 | 2023-06-23 | 艾伯维公司 | 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 |
| CN109475556A (zh) * | 2016-07-06 | 2019-03-15 | 伊马拉公司 | 用于治疗外周疾病的pde9抑制剂 |
| WO2020202183A1 (en) * | 2019-03-29 | 2020-10-08 | Mylan Laboratories Limited | The process for the preparation of upadacitinib and its intermediates |
-
2019
- 2019-08-26 ES ES19855338T patent/ES2997858T3/es active Active
- 2019-08-26 WO PCT/CN2019/102443 patent/WO2020043033A2/zh not_active Ceased
- 2019-08-26 PL PL19855338.0T patent/PL3845521T3/pl unknown
- 2019-08-26 HR HRP20250035TT patent/HRP20250035T1/hr unknown
- 2019-08-26 EP EP19855338.0A patent/EP3845521B1/en active Active
- 2019-08-26 HU HUE19855338A patent/HUE069611T2/hu unknown
- 2019-08-26 US US17/272,369 patent/US11926633B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20250035T1 (hr) | 2025-03-14 |
| ES2997858T3 (en) | 2025-02-18 |
| US20210323971A1 (en) | 2021-10-21 |
| EP3845521A2 (en) | 2021-07-07 |
| EP3845521C0 (en) | 2024-11-06 |
| HUE069611T2 (hu) | 2025-03-28 |
| WO2020043033A2 (zh) | 2020-03-05 |
| EP3845521B1 (en) | 2024-11-06 |
| EP3845521A4 (en) | 2022-08-24 |
| US11926633B2 (en) | 2024-03-12 |
| WO2020043033A3 (zh) | 2020-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201917181D0 (en) | No details | |
| GB201917180D0 (en) | No details | |
| GB201917178D0 (en) | No details | |
| IL280912A (en) | New methods | |
| GB201910775D0 (en) | No Details | |
| GB202017924D0 (en) | No details | |
| GB201801768D0 (en) | Synthesis method | |
| PT3609540T (pt) | Método de síntese de imunoconjugado | |
| GB201700937D0 (en) | Synthesis method | |
| GB201918422D0 (en) | No details | |
| IL272924A (en) | Methods for preparing and using endoxifen | |
| PL3845521T3 (pl) | Sposoby syntezy upadacytynibu i jego produktów pośrednich | |
| GB201701396D0 (en) | Novel alternating-phase synthesis method | |
| GB201719854D0 (en) | Sound effect synthesis | |
| GB201803724D0 (en) | Methods | |
| GB201802486D0 (en) | Methods | |
| GB201908106D0 (en) | No details | |
| GB201808121D0 (en) | Synthesis And Transfer Methods | |
| GB201805466D0 (en) | Methods | |
| GB202007832D0 (en) | No details | |
| GB201918330D0 (en) | No details | |
| SG11202007342QA (en) | Methods | |
| ZA202102231B (en) | Fischer-tropsch process | |
| EP3904340C0 (en) | PROCESSES FOR SYNTHESIS OF A HALOFUGINONE AND AN INTERMEDIATE THEREOF | |
| GB201814451D0 (en) | Methods |